Genetic testing for cystic fibrosis

Archives of Internal Medicine

Volumn 159, Issue 14, 1999, Pages 1529-1539

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; DEOXYRIBONUCLEASE; PANCREAS ENZYME; VITAMIN;

ARTICLE; CYSTIC FIBROSIS; ECONOMIC EVALUATION; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HEALTH EDUCATION; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN DIET;

CARRIERS; CLINICAL APPROACH/SOURCE; COLORADO; CONSENSUS; COSTS AND BENEFITS; FAMILY MEMBERS; GENETICS AND REPRODUCTION; PREGNANT WOMEN; RISKS AND BENEFITS; UNITED STATES; WISCONSIN;

CONSENSUS; CYSTIC FIBROSIS; DISCLOSURE; ETHNIC GROUPS; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMANS; INCIDENCE; INFORMED CONSENT; PHENOTYPE; POPULATION SURVEILLANCE; PREGNANT WOMEN; RISK ASSESSMENT; UNITED STATES;

EID: 0033606777     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.14.1529     Document Type: Article

References (62)

1. Asch DA, Hershey JC, Pauly MV, Patton JP, Jedrziewski MK, Mennuti MT. Genetic screening for reproductive planning: methodologic and conceptual issues in policy analysis. Am J Public Health. 1996;86:684-690.
2. Asch DA, Mennuti MT. Evolving policy questions in the use of genetic tests. IEEE Technol Soc. 1996;15:4-11.
3. Asch DA, Patton JP, Hershey JC, Mennuti MT. Reporting the results of cystic fibrosis carrier screening. Am J Obstet Gynecol. 1993;168:1-6.
4. Axworthy D, Brock DJH, Bobrow M, Marteau TM. Psychological impact of population-based carrier testing for cystic fibrosis: three year follow-up. Lancet. 1996;347: 1443-1446.
5. Beaudet AL. Carrier screening for cystic fibrosis Am J Hum Genet. 1990;47:603-605.
6. Bekker H, Modell M, Dennis G, et al. Uptake of cystic fibrosis carrier testing in primary care: supply push or demand pull? BMJ. 1993;306:1584-1586.
7. Bernhardt BB, Chase GA, Faden RR, et al. Educating patients about cystic fibrosis carrier screening in a primary care setting. Arch Fam Med. 1996;5:336-340.
8. Botkin JR. Fetal privacy and confidentiality. Hastings Cent Rep. 1995;25:32-39.
9. Brock DJH. Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet. 1996;347:148-150.
10. Callanan N, Bloom D, Sorenson J, DeVellis B, Cheuvront B. CF carrier testing: experience of relatives. J Gen Couns. 1995;4:83-95.
11. Chase GA, Bernhardt BA, Faden RR, Geller G, Tambor ES, Holtzman NA. Confirmation of a finding on tolerance for test uncertainty (TTU) incystic fibrosis carrier screening. Am J Hum Genet. 1995;57(suppl 4):A29.
12. Cheuvront B, Sorenson J, Callanan N, Stearns S, DeVellis B. Psychosocial and educational outcomes associated with home- and clinic-based pretest education and cystic fibrosis carrier testing among a population of at-risk relatives. Am J Med Genet. 1998;75:461-468.
13. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332:1475-1480.
14. Clayton EW, Hannig VH, Pfotenhauer JP, Parker RA, Campbell PW III, Phillips JA III. Teaching about cystic fibrosis carrier screening by using written and video information. Am J Hum Genet. 1995;57:171-181.
15. Clayton EW, Hannig VH, Pfotenhauer JP, Parker RA, Campbell PW III, Phillips JA III. Lack of interest by non-pregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet. 1996;58:617-627.
16. Congress of the United States, Office of Technology Assessment. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Washington, DC: US Government Printing Office; August 1992. Publication OTA-BA-532.
17. Cotton RGH. Current methods of mutation detection. Mutat Res. 1993;285:125-144.
18. Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum Mutat. 1994;4:167-177.
19. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256.
20. Doherty RA, Bradley LA, Haddow JE. Prenatal screening for cystic fibrosis: an updated perspective. Am J Obstet Gynecol. 1997;176:268-270.
21. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE. Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn. 1996;16: 397-404.
22. Doksum T, Bernhardt BA. Population-based carrier screening for cystic fibrosis. Clin Obstet Gynecol. 1996; 39:763-771.
23. Fang CY, Dunkel-Schetter C, Tatsugawa ZH, et al. Attitudes toward genetic carrier screening for cystic fibrosis in pregnant women: the role of health beliefs and avoidant coping style. Womens Health. 1997;3:31-51.
24. Fanos JH. Sibling Loss. Mahwah, NJ: Lawrence Erlbaum Associates; 1996.
25. Fanos JH. Developmental tasks of childhood and adolescence: implications for genetic testing. Am J Med Genet. 1997;71:22-28.
26. Fanos JH, Johnson JP. Perception of carrier status by cystic fibrosis siblings. Am J Hum Genet. 1995;57:431-438.
27. Fanos JH, Johnson JP. Barriers to carrier testing for adult siblings: the importance of not knowing. Am J Med Genet. 1995;59:85-91.
28. Farrell PM, Aronson RA, Hoffman G, Laessig RH. Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing. WMJ. 1994;93:415-421.
29. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. Adv Pediatr. 1992;39:31-64.
30. Grebe TA, Doane WW, Richter SF, et al. Mutation analysis of the cystic fibrosis transmembrane regulator gene in Native American populations of the Southwest. Am J Hum Genet. 1992;51:736-740.
31. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997; 99:819-824.
32. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet. 1993;52:616-626.
33. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, et al. PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet. 1997;60:935-947.
34. Grody WW, Kronquist KE, Lee EU, Edmond J, Rome LH. PCR-based cystic fibrosis carrier screening in a first-year medical student biochemistry laboratory. Am J Hum Genet. 1993;53:1352-1355.
35. Hacia JG, Brody LC, Chee MS, Fodor SPA, Collins FS. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-color fluorescence analysis. Nat Genet. 1996;14:441-447.
36. Haddow JE, Palomaki GE. Similarities in women's decision making in the US and UK during prenatal screening for Down's syndrome. Prenat Diagn. 1996;16:1161-1162.
37. Hamosh A, Fitzsimmons SC, Macek MJ, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998;132:255-259.
38. Lemna WK, Feldman GL, Kerem Bat-sheva, et al. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med. 1990; 322:291-296.
39. Levenkron JC, Loader S, Rowley PT. Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet. 1997;73:378-386.
40. Lieu TA, Watson SE, Washington AE. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol. 1994;84:903-912.
41. Loader S, Caldwell P, Kozyra A, et al. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet. 1996;59:234-247.
42. Marteau TM. Psychological consequences of cystic fibrosis heterozygote screening. In: Dodge J, Widdicombe J, Brock D, eds. Current Topics in Cystic Fibrosis. Vol 3. New York, NY: John Wiley & Sons Inc; 1993:165-180.
43. Marteau TM, Dundas R, Axworthy D. Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of gender and test result. Health Psychol. 1997;16:51-62.
44. Mercier B, Raguénès O, Estivill X, et al. Complete detection of mutations in cystic fibrosis of Native American origin. Hum Genet. 1994;94:629-632.
45. Myers MF, Bernhardt BA, Tambor ES, Holtzman NA. Involving consumers in the development of an educational program for cystic fibrosis carrier screening. Am J Hum Genet. 1994;54:719-726.
46. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N. Engl J Med. 1996;335:179-188.
47. Rosenfeld MA, Collins FS. Gene therapy for cystic fibrosis. Chest. 1996;109:241-252.
48. Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet. 1998;63:1160-1174.
49. Rowley PT, Loader S, Levenkron JC, Phelps CE. Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. Am J Prev Med. 1993;9:261-266.
50. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. 1996;12:280-287.
51. Shuber AP, Michalowsky LA, Nass GS, et al. High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes. Hum Mol Genet. 1997;6:337-347.
52. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85:231-236.
53. Sorenson J, Cheuvront B, Bruning A, et al. Proband and parent assistance in identifying relatives for cystic fibrosis carrier testing. Am J Med Genet. 1996;63:419-425.
54. Sorenson J, Cheuvront B, DeVellis B, et al. Acceptance of home and clinic based cystic fibrosis carrier education and testing by first, second, and third degree relatives of cystic fibrosis patients. Am J Med Genet 1997; 70:121-129.
55. Tambor ES, Bernhardt BA, Chase GA, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet. 1994; 55:626-637.
56. Tatsugawa Z, Fox MA, Fang C, et al. Education and testing strategy for large-scale cystic fibrosis carrier screening. J Genet Couns. 1994;3:279-289.
57. Wald NJ. Couple screening for cystic fibrosis. Lancet. 1991;338:1318-1319.
58. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill Book Co; 1995:3799-3876.
59. Wilfond BS, Fost N. The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990;263:2777-2783.
60. Wilfond BS, Fost N. The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations. Milbank Q. 1992;70:629-659.
61. Wilfond BS, Nolan K. National policy developments the clinical application of genetic diagnostic technologies: lessons from cystic fibrosis. JAMA. 1993;270:2948-2954.
62. Witt DR, Schaefer C, Hallam P, et al. Cystic fibrosis heterozygote screening in 5161 pregnant women. Am J Hum Genet. 1996;58:823-835.